Esperion Therapeutics Announces the Appointment of Scott Braunstein, M.D. to Board of Directors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Esperion Therapeutics (ESPR) Adds Scott Braunstein, M.D., as Director
June 15, 2015 8:31 AM EDTEsperion Therapeutics (NASDAQ: ESPR) announced the appointment of Scott Braunstein, M.D. as a Class III Director, with a term expiring at the 2016 annual meeting of stockholders.
"I'm very pleased to welcome Dr. Braunstein to the Esperion board," said Tim Mayleben, president and chief executive officer. "With an experience base which spans the healthcare sector -- first as a practicing physician and... More
